Skip to main content

Fluidigm Licenses Protein Crystallization Technology from Syrrx

NEW YORK, Feb. 3 (GenomeWeb News) - Microfluidics developer Fluidigm has obtained non-exclusive license rights to Syrrx's submicroliter protein crystallization technology, the companies said today.

The terms of the licensing agreement were not disclosed.

Syrrx said it obtained "broad patent protection" for the crystallization of proteins in submicroliter volumes through an exclusive license with Lawrence Berkeley National Laboratory. Fluidigm's non-exclusive license will provide it with freedom to operate relative to Syrrx's patent portfolio, the companies said.

Fluidigm said it acquired the license to support the commercialization of its Topaz protein crystallization platform, which relies on chips that consume only nanogram quantities of protein per trial.

David Weitz, Syrrx's general counsel, said in a statement that Fluidigm is the first system manufacturer to license the company's technology, and that Syrrx "looks forward to securing other licensees as submicroliter crystallization is more widely adopted."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.